Skip to search formSkip to main contentSkip to account menu

HBW 538

Known as: HBW-538 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tiprotimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Comparison of High and Normal Birth Weight Infants on Eating, Feeding Practices, and Subsequent Weight
Objectives High birth weight (HBW ≥ 4000 g) infants are at increased risk for obesity, but research has yet to identify the… 
1994
1994
Comparative study of the effects of cefodizime and HBW 538 in potentiating the production of reactive oxygen species by human polymorphonuclear leukocytes.
The immunomodulatory activity of cefodizime (CDZM), an aminothiazolylcephalosporin, was compared to that of HBW 538, a derivative… 
1991
1991
Immunophenotypization of cells involved in local immune response and serum antibodies in cephalosporin-treated mice.
The in vivo potency of cefodizime (HR 221), tiprotimod (a new synthetic thiazole derivative of HR 221, HBW 538) and cefotaxime to… 
1989
1989
Immunomodulation by the new synthetic thiazole derivative tiprotimod. 3rd communication: influence on host resistance to microorganisms, tumors and on experimental immune disorders.
To evaluate the influence of [2-(3-carboxy-1-probylthio)-4-methyl-1,3-thiazole]acetic acid (tiprotimod, HBW 538) on the host… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)